Gilead Sciences vs Pfizer Which Is Stronger?

Gilead Sciences and Pfizer are two prominent pharmaceutical companies that play a crucial role in the healthcare industry. Both companies have a strong track record of developing innovative drugs and treatments that have positively impacted millions of lives worldwide. Investors often compare the performance of Gilead Sciences and Pfizer stocks, analyzing factors such as financial performance, pipeline of products, and market prospects. Understanding the strengths and weaknesses of each company can help investors make informed decisions about their investment portfolios.

Gilead Sciences or Pfizer?

When comparing Gilead Sciences and Pfizer, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Gilead Sciences and Pfizer.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Gilead Sciences has a dividend yield of 3.95%, while Pfizer has a dividend yield of 6.4%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Gilead Sciences reports a 5-year dividend growth of 5.64% year and a payout ratio of 3862.70%. On the other hand, Pfizer reports a 5-year dividend growth of 4.08% year and a payout ratio of 221.76%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Gilead Sciences P/E ratio at 960.29 and Pfizer's P/E ratio at 34.91. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Gilead Sciences P/B ratio is 0.00 while Pfizer's P/B ratio is 1.61.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Gilead Sciences has seen a 5-year revenue growth of 0.27%, while Pfizer's is 0.13%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Gilead Sciences's ROE at 0.86% and Pfizer's ROE at 4.72%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $96.30 for Gilead Sciences and $26.22 for Pfizer. Over the past year, Gilead Sciences's prices ranged from $62.07 to $98.90, with a yearly change of 59.34%. Pfizer's prices fluctuated between $25.20 and $31.54, with a yearly change of 25.16%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.